Categories Earnings, Health Care

Avid Bioservices stock jumps after Q3 loss narrows on higher revenues

Avid Bioservices (CDMO) reported a narrower net loss for the third quarter of 2019, aided by a sharp increase in revenues and lower expenses. The results also topped analysts’ expectations. The company’s stock jumped about 4% during the extended trading session Monday following the announcement.

The Tustin, California-based biotech contract manufacturer reported a net loss attributable to common stockholders of $2.6 million or $0.05 per share for the third quarter, compared to a loss of $12.4 million or $0.28 per share a year earlier. Analysts had forecast a wider loss for the most recent quarter. Boosting the turnaround, selling, general & administrative expenses dropped 33% to $3.2 million.

Contract manufacturing revenues more than doubled to $13.8 million – far exceeding expectations – reflecting higher demand from a more diversified client base. The improved topline performance translated into positive gross margins, which recovered from a negative 61% to a positive 15% helped by a favorable product mix and higher volumes.

The improved topline performance translated into an improvement in gross margins helped by a favorable product mix and higher volumes.

During the three-month period, the management expanded several ongoing projects. The company said it is firmly on-track towards achieving profitability in the near term. The management currently expects to end the fiscal year within the lower half of its revenue guidance of $51-$55 million.

“The third quarter was busy and productive as reflected by our strong financial results. Our process development group is increasingly busy, now contributing over 20% of revenues.  With respect to new projects, we continue to see growth in the number of RFPs received,” said CEO Roger Lias.

Also see: Avid Bioservices Q3 2019 Earnings Conference Call Transcript

Recently, Abbott Laboratories (ABT) reported a net profit for the fourth quarter compared to a loss last year, helped by lower tax expense. The biotech firm swung to a profit of $0.37 per share even as worldwide sales moved up 2.3% aided by a strong performance by the Medical Devices and Diagnostics businesses.

Shares of Avid Bioservices closed Monday’s regular session sharply higher and gained further in the after-hours session, reversing the trend seen since the beginning of the year. The stock rose about 56% in the past twelve months but often underperformed the sector.

Earnings Transcript: Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

GameStop (GME) Earnings: Q1 loss narrows on 25% sales growth

Video game retailer GameStop Corp. (NYSE: GME), which has become the talk of the town after the unprecedented stock rally in recent weeks, reported a narrower loss for the first

Should you invest in Steel Dynamics (STLD) stock after 78% rally?

The steel industry managed to shrug off the pandemic blues earlier than expected as the recovery in industrial activity pushed up demand. With the vaccination drive and the government’s aggressive

Campbell Soup (CPB) Q3 Earnings: Key financials and quarterly highlights

Campbell Soup Company (NYSE: CPB) reported third-quarter 2021 earnings results today. Net sales decreased 11% year-over-year to $1.98 billion, as a result of lapping the demand surge at the onset

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top